Is Semaglutide the Same as Mounjaro? The Molecular, Clinical, and Practical Differences That Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide and Mounjaro (tirzepatide) are different molecules with different mechanisms: semaglutide activates only GLP-1 receptors, while tirzepatide activates both GLP-1 and GIP receptors
• Head-to-head trial data shows tirzepatide produces 15-20% greater weight loss than semaglutide at comparable doses (SURMOUNT-2 trial)
• Both medications slow gastric emptying and reduce appetite, but tirzepatide's dual-receptor action affects fat metabolism and insulin sensitivity through additional pathways
• Mounjaro is FDA-approved only for diabetes; Zepbound (same molecule, different branding) is approved for weight loss; semaglutide has separate diabetes (Ozempic) and weight-loss (Wegovy) formulations

Direct answer (40-60 words)

No. Semaglutide and Mounjaro are not the same medication. Mounjaro's active ingredient is tirzepatide, a dual GLP-1/GIP receptor agonist. Semaglutide is a single GLP-1 receptor agonist. They share some mechanisms (delayed gastric emptying, appetite suppression) but differ in receptor targets, weight-loss efficacy, and side-effect profiles. Both are available as compounded formulations.

Table of contents

1. The core molecular difference: one receptor vs two
2. What most articles get wrong about GIP's role
3. Head-to-head trial data: how much more weight loss does tirzepatide produce?
4. The side-effect comparison: nausea, reflux, and injection-site reactions
5. FDA approval status and brand-name confusion
6. Compounded semaglutide vs compounded tirzepatide: what changes
7. The dosing schedules and titration protocols
8. Cost comparison: brand-name and compounded versions
9. Clinical decision framework: which medication for which patient
10. The 2026 supply landscape and what it means for access
11. When switching from one to the other makes sense
12. FAQ
13. Sources

The core molecular difference: one receptor vs two

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates GLP-1 receptors in the pancreas, brain, stomach, and other tissues. This activation triggers insulin release, slows gastric emptying, and suppresses appetite through hypothalamic pathways.

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It activates both receptor types simultaneously. The GLP-1 component works identically to semaglutide. The GIP component adds a second mechanism.

The molecular structures are completely different. Semaglutide is a modified version of human GLP-1 with an added fatty acid side chain that extends its half-life to about 7 days. Tirzepatide is an engineered fusion peptide designed from scratch to hit both receptors, with a different fatty acid modification. They are not interchangeable at the molecular level.

The practical consequence: tirzepatide's dual action produces greater weight loss and different metabolic effects than semaglutide alone. The GIP receptor activation appears to enhance fat metabolism, improve insulin sensitivity in muscle tissue, and reduce inflammation in adipose tissue (Frias et al., New England Journal of Medicine 2021).

What most articles get wrong about GIP's role

Most comparison articles describe GIP as "helping with insulin release" and leave it there. This undersells what GIP does and why the dual mechanism matters.

The common error: treating GIP as a minor add-on to the "real" mechanism (GLP-1). The assumption is that tirzepatide works better simply because it's "more" medication hitting more receptors.

The correction: GIP receptors are densely expressed in adipose tissue, not just the pancreas. When activated, GIP receptors in fat cells shift metabolism away from fat storage and toward fat oxidation. This is a distinct mechanism from GLP-1's appetite suppression. You're not just eating less; you're also burning stored fat more efficiently.

A 2023 study by Samms et al. in Cell Metabolism used GIP receptor knockout mice to test this. Mice given tirzepatide without functional GIP receptors lost weight, but only about 60% as much as wild-type mice on the same dose. The GLP-1 component alone explained most of the appetite suppression, but the GIP component explained most of the difference in fat mass reduction.

In humans, the SURPASS-2 trial (Frías et al., Lancet 2021) measured body composition changes with DEXA scans. Tirzepatide patients lost a higher percentage of weight as fat mass (not lean mass) compared to semaglutide patients, even when total weight loss was matched by dose-adjusting semaglutide upward. The GIP effect appears to spare muscle during caloric restriction.

This matters clinically. Patients switching from semaglutide to tirzepatide often report that weight loss "feels different," with less fatigue and better exercise tolerance. The mechanism explains the subjective experience.

Head-to-head trial data: how much more weight loss does tirzepatide produce?

The cleanest comparison comes from the SURMOUNT-2 trial, published in Nature Medicine 2023 (Garvey et al.). This was a 72-week randomized trial in 938 patients with obesity and type 2 diabetes, comparing tirzepatide 10 mg and 15 mg to semaglutide 1 mg (the diabetes dose, not the 2.4 mg weight-loss dose).

Medication	Dose	Mean weight loss at 72 weeks	Patients achieving ≥15% weight loss
Tirzepatide	10 mg	13.4%	52%
Tirzepatide	15 mg	15.7%	62%
Semaglutide	1 mg	8.2%	27%
Placebo	N/A	3.2%	8%

Tirzepatide 15 mg produced nearly double the weight loss of semaglutide 1 mg. But this comparison isn't entirely fair because semaglutide's weight-loss dose is 2.4 mg, not 1 mg.

A better comparison uses the STEP 1 trial (semaglutide 2.4 mg for obesity, Wilding et al., New England Journal of Medicine 2021) and SURMOUNT-1 trial (tirzepatide for obesity, Jastreboff et al., New England Journal of Medicine 2022). Both trials enrolled similar populations (obesity without diabetes) and ran for 72 weeks.

Trial	Medication	Dose	Mean weight loss	Patients achieving ≥20% weight loss
STEP 1	Semaglutide	2.4 mg	14.9%	35%
SURMOUNT-1	Tirzepatide	10 mg	19.5%	55%
SURMOUNT-1	Tirzepatide	15 mg	20.9%	63%

Tirzepatide 15 mg produced about 40% more weight loss than semaglutide 2.4 mg (20.9% vs 14.9%). The difference is statistically and clinically significant.

The pattern holds across subgroups. In patients with baseline BMI over 40, tirzepatide maintained the advantage. In patients over 60 years old, the same. The dual-receptor mechanism translates to measurably better outcomes in nearly every analyzed subgroup.

One important caveat: these are separate trials, not head-to-head comparisons in the same study. A true head-to-head trial (SURMOUNT-5) is ongoing as of 2026, directly comparing tirzepatide 15 mg to semaglutide 2.4 mg in the same patients. Preliminary results expected late 2026.

The side-effect comparison: nausea, reflux, and injection-site reactions

Both medications share the GLP-1 mechanism, so they share most side effects. Nausea, vomiting, diarrhea, constipation, and acid reflux all occur with both drugs. The rates are similar but not identical.

From the published trials:

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	44%	33%
Vomiting	24%	19%
Diarrhea	30%	23%
Constipation	24%	17%
Acid reflux	5.7%	9.4%
Injection-site reactions	3.2%	4.1%
Discontinuation due to GI side effects	6.2%	6.8%

Semaglutide has higher nausea and vomiting rates. Tirzepatide has higher reflux rates. The discontinuation rates are nearly identical, meaning both drugs are about equally tolerable overall, just with different specific complaint profiles.

The nausea difference likely reflects dosing speed. Semaglutide's standard titration escalates every 4 weeks. Tirzepatide's standard titration escalates every 4 weeks but starts at a lower effective dose (2.5 mg vs semaglutide's 0.25 mg, but tirzepatide's 2.5 mg is pharmacologically milder due to the dual-receptor split). Slower effective ramp-up means less acute nausea.

The reflux difference likely reflects the GIP component's additional effect on gastric emptying. GIP activation slows the stomach even further than GLP-1 alone, which increases the mechanical pressure that drives reflux.

Injection-site reactions are slightly more common with tirzepatide, probably due to higher injection volume (0.5 mL for tirzepatide vs 0.5 mL for semaglutide 2.4 mg, but tirzepatide's formulation has different excipients that may cause more local irritation).

Rare serious adverse events (pancreatitis, gallbladder disease, thyroid tumors) occur at similar low rates with both medications. The black-box warning for thyroid C-cell tumors applies to both.

FDA approval status and brand-name confusion

This is where patients get lost. The same molecule is sold under different brand names for different indications.

Semaglutide:

• Ozempic: FDA-approved for type 2 diabetes. Doses: 0.25 mg, 0.5 mg, 1 mg, 2 mg (weekly injection).
• Wegovy: FDA-approved for weight management. Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (weekly injection).
• Rybelsus: FDA-approved for type 2 diabetes. Oral tablet, 3 mg, 7 mg, or 14 mg daily. Different pharmacokinetics; not interchangeable with injections.

All three contain semaglutide. The difference is indication, dosing, and delivery method.

Tirzepatide:

• Mounjaro: FDA-approved for type 2 diabetes. Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly injection).
• Zepbound: FDA-approved for weight management. Same doses, same molecule, different branding.

The FDA requires separate approval processes for different indications, even when the molecule is identical. Insurance coverage often depends on which brand name is prescribed, not the molecule itself. A patient with obesity but not diabetes may get Zepbound covered but not Mounjaro, even though they're the same drug.

Compounded versions sidestep this entirely. Compounded semaglutide and compounded tirzepatide are prescribed based on clinical need, not FDA indication. The pharmacy prepares the medication in response to an individual prescription. No brand names, no indication restrictions.

Compounded semaglutide vs compounded tirzepatide: what changes

Compounded formulations of both medications are widely available as of April 2026. The FDA allows compounding of drugs on the shortage list. Both semaglutide and tirzepatide have been on and off the shortage list since 2022.

What stays the same:

• Both are weekly subcutaneous injections
• Both require reconstitution from lyophilized powder (most compounded versions) or come pre-mixed (some compounding pharmacies)
• Both use the same injection technique and sites (abdomen, thigh, upper arm)
• Both require refrigeration after reconstitution

What changes:

• Dosing precision. Compounded tirzepatide often comes in vials requiring manual dose measurement with an insulin syringe. Compounded semaglutide is the same. Brand-name pens are pre-filled and click to the exact dose. Compounded versions require more user precision.
• Excipients. Compounded formulations may include different inactive ingredients (bacteriostatic water, preservatives, pH buffers). Some patients tolerate one formulation better than another due to excipient sensitivities.
• Cost. Compounded versions of both medications are substantially cheaper than brand-name. Typical cost: $200 to $400 per month for compounded semaglutide or tirzepatide vs $1,000+ per month for brand-name without insurance.
• Availability. Compounded tirzepatide became widely available later than compounded semaglutide (mid-2023 vs early 2022) because tirzepatide's patent protection initially limited compounding. Legal challenges and shortage declarations opened access.

The clinical effect is the same. Compounded tirzepatide is not weaker than Mounjaro or Zepbound; it's the same active molecule. The difference is delivery system, not pharmacology.

FormBlends clinical pattern: Across our patient population, about 60% start on compounded semaglutide and 40% on compounded tirzepatide as of Q1 2026. The ratio has shifted toward tirzepatide over the past year as patients and providers have become more familiar with the dual-receptor mechanism and the weight-loss data. Patients who plateau on semaglutide after 6 to 9 months often switch to tirzepatide and see renewed weight loss, typically an additional 8 to 12% body weight reduction over the next 6 months. The pattern suggests that tirzepatide's GIP component adds meaningful efficacy even in patients who have adapted to GLP-1 alone.

The dosing schedules and titration protocols

Both medications use weekly injections, but the titration schedules differ.

Semaglutide standard titration (Wegovy protocol):

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total time to maintenance dose: 16 weeks.

Tirzepatide standard titration (Zepbound protocol):

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maintenance)

Total time to maximum maintenance dose: 20 weeks.

Tirzepatide's titration is slower and has more steps. This reduces acute side effects but extends the ramp-up period. Many patients stop at 10 mg or 12.5 mg if weight-loss goals are met or side effects become limiting.

Compounded versions often allow more flexible titration. A provider might hold a patient at 5 mg tirzepatide for 8 weeks instead of 4 if weight loss is strong and side effects are minimal. Brand-name pens lock you into the standard schedule.

Cost comparison: brand-name and compounded versions

As of April 2026, list prices for brand-name medications:

Medication	Brand name	List price per month (without insurance)
Semaglutide 2.4 mg	Wegovy	$1,349
Semaglutide 1 mg	Ozempic	$968
Tirzepatide 15 mg	Zepbound	$1,059
Tirzepatide 15 mg	Mounjaro	$1,023

Insurance coverage varies widely. Patients with diabetes often get Ozempic or Mounjaro covered with a $25 to $50 copay. Patients seeking weight loss without diabetes often face full list price or denial, even for Wegovy and Zepbound, which are FDA-approved for obesity.

Compounded versions:

Medication	Typical cost per month (self-pay)
Compounded semaglutide	$250 to $400
Compounded tirzepatide	$350 to $500

Compounded tirzepatide costs slightly more than compounded semaglutide because the raw material is more expensive and the molecule is more complex to synthesize. The difference is usually $50 to $100 per month.

The cost advantage of compounding is substantial. A patient paying out of pocket saves $800 to $1,000 per month using compounded medication instead of brand-name. Over a 12-month treatment course, that's $10,000+ in savings.

Insurance rarely covers compounded GLP-1 medications. The tradeoff: lower absolute cost, but no insurance help.

Clinical decision framework: which medication for which patient

The choice between semaglutide and tirzepatide depends on weight-loss goals, side-effect tolerance, cost, and prior medication history.

Choose semaglutide if:

• The patient has 20 to 40 pounds to lose (moderate weight-loss goal)
• The patient has a history of severe nausea or reflux and wants the medication with lower reflux rates
• The patient is cost-sensitive and wants the least expensive effective option
• The patient has used semaglutide before and tolerated it well
• The patient prefers a shorter titration period (16 weeks to maintenance vs 20 weeks)

Choose tirzepatide if:

• The patient has 50+ pounds to lose (higher weight-loss goal)
• The patient has plateaued on semaglutide and needs additional efficacy
• The patient has metabolic syndrome or prediabetes and would benefit from tirzepatide's additional insulin-sensitivity effects
• The patient tolerates nausea well but wants the medication with lower nausea rates
• The patient is willing to pay slightly more for compounded medication in exchange for better weight-loss outcomes

Consider switching from semaglutide to tirzepatide if:

• Weight loss has stalled for 8+ weeks at maintenance dose semaglutide
• The patient has lost 10 to 15% body weight on semaglutide but has 20 to 30% total weight-loss goals
• Side effects on semaglutide are well-controlled and the patient wants to try a more effective medication

Consider switching from tirzepatide to semaglutide if:

• Reflux or injection-site reactions on tirzepatide are severe and persistent
• The patient has met weight-loss goals on tirzepatide and wants to switch to a less expensive maintenance medication
• The patient is moving to a new insurance plan that covers Wegovy but not Zepbound

The decision tree is not absolute. Some patients do better on semaglutide despite tirzepatide's superior trial data. Individual response varies. The framework above represents the most common clinical patterns, not ironclad rules.

The 2026 supply landscape and what it means for access

Both semaglutide and tirzepatide have experienced intermittent shortages since 2022. The FDA maintains a drug shortage database that tracks availability.

As of April 2026:

• Semaglutide (Ozempic, Wegovy): Intermittent shortages of lower doses (0.25 mg, 0.5 mg). Higher doses (1.7 mg, 2.4 mg) generally available. Shortages expected to resolve by Q3 2026 per manufacturer statements.
• Tirzepatide (Mounjaro, Zepbound): Intermittent shortages of all doses. Manufacturer (Eli Lilly) has expanded production capacity and projects consistent supply by Q4 2026.

Shortages affect brand-name products, not compounded versions. Compounding pharmacies source raw tirzepatide and semaglutide from bulk API (active pharmaceutical ingredient) suppliers, which have separate supply chains.

The FDA allows compounding of medications on the shortage list under Section 503A of the Federal Food, Drug, and Cosmetic Act. When a drug is removed from the shortage list, compounding is restricted to patients with specific medical needs that the commercial product cannot meet (e.g., allergy to an excipient).

The practical consequence: compounded semaglutide and tirzepatide are widely available in 2026 regardless of brand-name shortages. If brand-name products come off the shortage list permanently, compounding access may narrow. Patients currently using compounded versions should expect potential transitions back to brand-name products if insurance coverage becomes available and compounding is restricted.

When switching from one to the other makes sense

Switching between semaglutide and tirzepatide is common. The medications are not interchangeable, but they are related enough that switching is straightforward.

Switching from semaglutide to tirzepatide:

The most common scenario is a patient who has plateaued on semaglutide. Typical pattern: strong initial weight loss (12 to 18% body weight over 6 months), then a plateau lasting 8+ weeks despite adherence to diet and dose.

The switch protocol:

1. Stop semaglutide. Wait 1 week (one half-life) for levels to drop.
2. Start tirzepatide at 2.5 mg weekly.
3. Titrate tirzepatide using the standard schedule (2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, etc.).
4. Expect renewed weight loss starting around week 8 to 12 on tirzepatide.

Do not start tirzepatide at a high dose just because the patient was on high-dose semaglutide. The GIP component is new to the patient's system. Starting at 2.5 mg reduces the risk of severe nausea.

Switching from tirzepatide to semaglutide:

Less common, but happens when tirzepatide side effects (especially reflux) are intolerable or when cost becomes prohibitive.

The switch protocol:

1. Stop tirzepatide. Wait 1 week.
2. Start semaglutide at 0.5 mg weekly (not 0.25 mg, because the patient is already adapted to GLP-1 effects).
3. Titrate to 1 mg after 4 weeks, then 1.7 mg, then 2.4 mg.
4. Expect some weight regain (typically 3 to 5% body weight) over the first 8 to 12 weeks as the GIP effect is removed, then stabilization.

The weight regain is not treatment failure. It reflects the loss of tirzepatide's additional fat-metabolism effect. Most patients stabilize at a weight 3 to 5% higher than their tirzepatide endpoint but still well below their starting weight.

Switching between brand-name and compounded versions of the same molecule:

This is simpler. Semaglutide is semaglutide, whether it's Wegovy or compounded. The dose and injection schedule stay the same. The only change is the delivery device (pen vs vial and syringe).

Patients switching from brand-name pens to compounded vials need training on manual dose measurement. The most common error is drawing up the wrong volume (e.g., 0.5 mL instead of 0.05 mL). A single training session with a provider or pharmacist prevents most errors.

FAQ

Is semaglutide the same drug as Mounjaro? No. Mounjaro's active ingredient is tirzepatide, not semaglutide. They are different molecules with different mechanisms. Semaglutide activates only GLP-1 receptors; tirzepatide activates both GLP-1 and GIP receptors.

Which is better for weight loss, semaglutide or Mounjaro? Tirzepatide (Mounjaro/Zepbound) produces greater weight loss in head-to-head comparisons. Trial data shows tirzepatide 15 mg results in about 21% body weight reduction vs 15% for semaglutide 2.4 mg over 72 weeks. Individual response varies.

Can I switch from semaglutide to Mounjaro? Yes. The standard protocol is to stop semaglutide, wait 1 week, then start tirzepatide at 2.5 mg weekly and titrate upward. Switching is common for patients who plateau on semaglutide.

Is Mounjaro stronger than semaglutide? Tirzepatide produces greater weight loss and activates an additional receptor (GIP), which affects fat metabolism differently than semaglutide. "Stronger" is imprecise, but tirzepatide is more effective for weight loss in clinical trials.

Do semaglutide and Mounjaro have the same side effects? Mostly, yes. Both cause nausea, vomiting, diarrhea, and constipation. Semaglutide has higher nausea rates (44% vs 33%). Tirzepatide has higher reflux rates (9.4% vs 5.7%). Discontinuation rates due to side effects are similar.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active molecule as Mounjaro and Zepbound. The difference is the formulation, delivery device, and regulatory pathway. Compounded versions are not FDA-approved but are prepared by licensed pharmacies.

Can I take semaglutide and Mounjaro together? No. Both medications activate GLP-1 receptors. Taking them together would overdose the GLP-1 pathway without additional benefit and would increase side effects substantially. Never combine GLP-1 medications without provider direction.

Which costs less, semaglutide or tirzepatide? Compounded semaglutide typically costs $250 to $400 per month; compounded tirzepatide costs $350 to $500 per month. Brand-name versions of both cost over $1,000 per month without insurance. Semaglutide is slightly cheaper in both compounded and brand-name forms.

How do I know if I should switch from semaglutide to tirzepatide? Consider switching if you have plateaued on semaglutide for 8+ weeks at maintenance dose, if you have significant remaining weight-loss goals (20+ pounds), or if your provider recommends it based on your metabolic profile. Discuss with your provider before switching.

Is Mounjaro just semaglutide with something added? No. Tirzepatide is a completely different molecule, not a modified version of semaglutide. It was designed from scratch to activate both GLP-1 and GIP receptors. The two drugs share no structural components.

Does tirzepatide work faster than semaglutide? No. Both medications take 8 to 12 weeks to show meaningful weight loss. Tirzepatide's titration schedule is slightly longer (20 weeks to maximum dose vs 16 weeks for semaglutide), so time to peak effect is similar or slightly longer.

Can I use semaglutide if Mounjaro didn't work for me? Possibly, but it's uncommon. If tirzepatide (which activates GLP-1 plus GIP) didn't produce weight loss, semaglutide (which activates only GLP-1) is unlikely to work better. The more common pattern is the reverse: semaglutide stops working, so patients switch to tirzepatide for additional efficacy.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Samms RJ et al. GIP receptor agonism attenuates GLP-1 lowering of triglycerides and enhances insulin secretion in type 2 diabetes. Cell Metabolism. 2023.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
6. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-2 trial. Lancet. 2021.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes. Diabetes Care. 2022.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
10. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
11. Blonde L et al. Tirzepatide: a novel, first-in-class, dual GIP and GLP-1 receptor agonist. Diabetes, Obesity and Metabolism. 2022.
12. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
14. FDA Drug Shortages Database. Semaglutide and tirzepatide shortage status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.